

Australian Government

Department of Health Therapeutic Goods Administration

SERIOUS SHORTAGE SUBSTITUTION NOTICE

Notice Reference Number	SSSN 21-01
-------------------------	------------

This Notice applies for the following dates

From 01/01/20	21 To	30/06/2021
----------------------	--------------	------------

This Notice applies only to the following medicine

Name of medicine in shortage (including strength and formulation):	ESTRADOT 25 estradiol 25 microgram transdermal drug delivery system sachet (ARTG 97562)
Schedule:	S4: Prescription Only Medicine

Details of medicine to be supplied under this SSSN

Name of medicine (including strength and formulation) to be supplied	ESTRADERM MX 25 estradiol 25 microgram/24 hours (0.75mg) transdermal drug delivery system sachet (ARTG 67089) OR CLIMARA 25 estradiol 25 microgram/day transdermal drug delivery system sachet (ARTG 73962)
Same formulation but different strength?	No, See dosage substitution table below
Same active but different salt?	No
Different dose form?	No



Dosage substitution table

Original medicine dose: ESTRADOT 25	1 patch applied twice a week
Substitute medicine dose: ESTRADERM MX 25	1 patch applied twice a week
Substitute medicine dose: CLIMARA 25	1 patch applied once a week
Any restrictions on this dose form (e.g. dose intervals)	The patch size and dose interval varies between brands. The patch must not be cut or torn.
Any limitations on substitution	N/A
Quantity of this formulation (if applicable)	If dispensing Climara as the substitute medicine, only half the number of patches specified in the original prescription for Estradot will be required.

Conditions:

- Total quantity supplied under this protocol must be equivalent to the number of days supplied on original prescription.
- The patient/carer must provide a valid prescription for the original medicine that is in shortage.
- The patient/carer must consent to receiving a substitute medicine supplied pursuant to the notice.
- The pharmacist may, in their professional judgement, determine that the patient is not suitable to receive alternative medicine under the notice e.g. known previous hypersensitivity or severe adverse reaction to excipients.